LT3596041T - Terapinių medžiagų, skirtų intraląsteliniam tiekimui, junginys ir sudėtys - Google Patents

Terapinių medžiagų, skirtų intraląsteliniam tiekimui, junginys ir sudėtys

Info

Publication number
LT3596041T
LT3596041T LTEPPCT/US2018/022717T LT18022717T LT3596041T LT 3596041 T LT3596041 T LT 3596041T LT 18022717 T LT18022717 T LT 18022717T LT 3596041 T LT3596041 T LT 3596041T
Authority
LT
Lithuania
Prior art keywords
compositions
compound
therapeutic agents
intracellular delivery
intracellular
Prior art date
Application number
LTEPPCT/US2018/022717T
Other languages
English (en)
Lithuanian (lt)
Inventor
Kerry E. BENENATO
Ellalahewage Sathyajith Kumarasinghe
Mark Cornebise
Original Assignee
Modernatx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modernatx, Inc. filed Critical Modernatx, Inc.
Publication of LT3596041T publication Critical patent/LT3596041T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/06—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/20—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/36—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/10—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/36—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/38—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/14—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/12—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/28—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/30—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to nitro or nitroso groups
    • C07C279/32—N-nitroguanidines
    • C07C279/36—Substituted N-nitroguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/04—Diamides of sulfuric acids
    • C07C307/06—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/64—X and Y being nitrogen atoms, e.g. N-sulfonylguanidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/06—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms
    • C07C335/08—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C07F9/4009—Esters containing the structure (RX)2P(=X)-alk-N...P (X = O, S, Se)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
LTEPPCT/US2018/022717T 2017-03-15 2018-03-15 Terapinių medžiagų, skirtų intraląsteliniam tiekimui, junginys ir sudėtys LT3596041T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762471937P 2017-03-15 2017-03-15
US201762475140P 2017-03-22 2017-03-22
PCT/US2018/022717 WO2018170306A1 (en) 2017-03-15 2018-03-15 Compounds and compositions for intracellular delivery of therapeutic agents

Publications (1)

Publication Number Publication Date
LT3596041T true LT3596041T (lt) 2023-01-25

Family

ID=61874010

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2018/022717T LT3596041T (lt) 2017-03-15 2018-03-15 Terapinių medžiagų, skirtų intraląsteliniam tiekimui, junginys ir sudėtys

Country Status (22)

Country Link
US (2) US10857105B2 (cg-RX-API-DMAC7.html)
EP (2) EP4186888B1 (cg-RX-API-DMAC7.html)
JP (2) JP7167049B2 (cg-RX-API-DMAC7.html)
KR (1) KR20190132405A (cg-RX-API-DMAC7.html)
CN (1) CN110520409A (cg-RX-API-DMAC7.html)
AU (2) AU2018234692B2 (cg-RX-API-DMAC7.html)
CA (1) CA3056132A1 (cg-RX-API-DMAC7.html)
DK (1) DK3596041T3 (cg-RX-API-DMAC7.html)
ES (1) ES2940259T3 (cg-RX-API-DMAC7.html)
FI (1) FI3596041T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20230063T1 (cg-RX-API-DMAC7.html)
HU (1) HUE060693T2 (cg-RX-API-DMAC7.html)
IL (2) IL298380A (cg-RX-API-DMAC7.html)
LT (1) LT3596041T (cg-RX-API-DMAC7.html)
MX (1) MX2019011004A (cg-RX-API-DMAC7.html)
PL (1) PL3596041T3 (cg-RX-API-DMAC7.html)
PT (1) PT3596041T (cg-RX-API-DMAC7.html)
RS (1) RS63953B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201907916TA (cg-RX-API-DMAC7.html)
SI (1) SI3596041T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202300097T1 (cg-RX-API-DMAC7.html)
WO (1) WO2018170306A1 (cg-RX-API-DMAC7.html)

Families Citing this family (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
ES3009962T3 (en) 2014-04-23 2025-03-31 Modernatx Inc Nucleic acid vaccines
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
MA42543A (fr) 2015-07-30 2018-06-06 Modernatx Inc Arn épitope peptidiques concatémériques
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
ES2910425T3 (es) 2015-09-17 2022-05-12 Modernatx Inc Compuestos y composiciones para la administración intracelular de agentes terapéuticos
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
PE20181529A1 (es) 2015-10-22 2018-09-26 Modernatx Inc Vacunas de acido nucleico para el virus varicela-zoster (vzv)
CA3002922A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
MD3718565T2 (ro) 2015-10-22 2022-09-30 Modernatx Inc Vaccinuri împotriva virusului respirator
AU2016366978B2 (en) 2015-12-10 2022-07-28 Modernatx, Inc. Compositions and methods for delivery of therapeutic agents
SMT202200252T1 (it) 2015-12-22 2022-07-21 Modernatx Inc Composti e composizioni per il rilascio intracellulare di agenti
US12128113B2 (en) 2016-05-18 2024-10-29 Modernatx, Inc. Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
WO2018053209A1 (en) 2016-09-14 2018-03-22 Modernatx, Inc. High purity rna compositions and methods for preparation thereof
EP3528821A4 (en) 2016-10-21 2020-07-01 ModernaTX, Inc. HUMAN CYTOMEGALOVIRUS VACCINE
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
CN110167587A (zh) 2016-11-11 2019-08-23 摩登纳特斯有限公司 流感疫苗
US11384352B2 (en) 2016-12-13 2022-07-12 Modernatx, Inc. RNA affinity purification
CA3056133A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Crystal forms of amino lipids
CA3055653A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Lipid nanoparticle formulation
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
MA47787A (fr) 2017-03-15 2020-01-22 Modernatx Inc Vaccin contre le virus respiratoire syncytial
SI3596041T1 (sl) 2017-03-15 2023-02-28 Modernatx, Inc. Spojina in sestavki za intracelično dostavljanje terapevtskih sredstev
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
EP3609534A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. WIDE SPECTRUM INFLUENZA VIRUS VACCINE
EP3595676A4 (en) 2017-03-17 2021-05-05 Modernatx, Inc. RNA VACCINES AGAINST ZOONOSES
MA48047A (fr) 2017-04-05 2020-02-12 Modernatx Inc Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
EP3638678B1 (en) 2017-06-14 2025-12-03 ModernaTX, Inc. Compounds and compositions for intracellular delivery of agents
EP3638215A4 (en) 2017-06-15 2021-03-24 Modernatx, Inc. RNA FORMULATIONS
EP3668977A4 (en) 2017-08-18 2021-04-21 Modernatx, Inc. HPLC ANALYTICAL PROCESSES
EP3668979A4 (en) 2017-08-18 2021-06-02 Modernatx, Inc. METHOD OF HPLC ANALYSIS
EP3668971B8 (en) 2017-08-18 2024-05-29 ModernaTX, Inc. Rna polymerase variants
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. METHODS OF MANUFACTURING LIPID NANOPARTICLES
US10653767B2 (en) 2017-09-14 2020-05-19 Modernatx, Inc. Zika virus MRNA vaccines
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
WO2019152557A1 (en) * 2018-01-30 2019-08-08 Modernatx, Inc. Compositions and methods for delivery of agents to immune cells
MA52709A (fr) * 2018-05-23 2021-03-31 Modernatx Inc Administration d'adn
CN112399860B (zh) 2018-06-06 2024-08-16 麻省理工学院 用于在真核细胞中翻译的环状rna
US12263248B2 (en) 2018-09-19 2025-04-01 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
MA53650A (fr) 2018-09-19 2021-07-28 Modernatx Inc Lipides peg et leurs utilisations
AU2019345067A1 (en) 2018-09-19 2021-04-08 Modernatx, Inc. High-purity peg lipids and uses thereof
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
US20220009878A1 (en) * 2018-10-02 2022-01-13 Intellia Therapeutics, Inc. Ionizable amine lipids
EP4379053A3 (en) 2018-10-09 2024-09-18 The University of British Columbia Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto
JP7545395B2 (ja) 2019-01-31 2024-09-04 モデルナティエックス インコーポレイテッド ボルテックスミキサならびにその関連する方法、システム、及び装置
CA3128215A1 (en) 2019-01-31 2020-08-06 Modernatx, Inc. Methods of preparing lipid nanoparticles
CN113795579A (zh) 2019-02-20 2021-12-14 摩登纳特斯有限公司 用于共转录加帽的rna聚合酶变体
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
KR20210149727A (ko) 2019-03-11 2021-12-09 모더나티엑스, 인크. 유가식(fed-batch) 시험관내 전사 공정
EP3938379A4 (en) 2019-03-15 2023-02-22 ModernaTX, Inc. Hiv rna vaccines
CA3139032A1 (en) 2019-05-22 2020-11-26 Robert Alexander WESSELHOEFT Circular rna compositions and methods
WO2021026358A1 (en) * 2019-08-07 2021-02-11 Moderna TX, Inc. Compositions and methods for enhanced delivery of agents
CN120423969A (zh) 2019-09-19 2025-08-05 摩登纳特斯有限公司 用于治疗剂的细胞内递送的支链尾端脂质化合物和组合物
KR20220103923A (ko) * 2019-09-19 2022-07-25 모더나티엑스, 인크. 치료제의 세포내 전달을 위한 신규한 헤드기 지질 화합물 및 조성물
US20220411361A1 (en) * 2019-09-19 2022-12-29 Modernatx, Inc. Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents
EP4289951A3 (en) * 2019-12-04 2024-03-13 Orna Therapeutics, Inc. Circular rna compositions and methods
CA3163161A1 (en) 2020-01-09 2021-07-15 Gregory Lawrence HAMILTON Nanomaterials
JP2023513043A (ja) 2020-01-31 2023-03-30 モデルナティエックス インコーポレイテッド 脂質ナノ粒子を調製する方法
CN111349014A (zh) * 2020-03-30 2020-06-30 绵阳达高特新材料有限公司 一种方酸甲胺甲酯的制备方法
EP4126813A1 (en) * 2020-04-01 2023-02-08 Translate Bio, Inc. Phenolic acid lipid based cationic lipids
IL297084A (en) 2020-04-09 2022-12-01 Suzhou Abogen Biosciences Co Ltd Lipid nanoparticle compounds
CN113874507A (zh) 2020-04-09 2021-12-31 苏州艾博生物科技有限公司 冠状病毒的核酸疫苗
WO2021213924A1 (en) 2020-04-22 2021-10-28 BioNTech SE Coronavirus vaccine
US20230277457A1 (en) 2020-08-06 2023-09-07 Modernatx, Inc. Methods of preparing lipid nanoparticles
CN114073677B (zh) * 2020-08-20 2023-06-09 深圳深信生物科技有限公司 一种脂质纳米颗粒
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
CN112129871B (zh) * 2020-09-04 2021-06-15 斯微(上海)生物科技有限公司 复合磷脂脂质体中dope和m5两种磷脂含量的检测方法
JP2023549011A (ja) 2020-09-15 2023-11-22 ヴァーヴ・セラピューティクス，インコーポレーテッド 遺伝子編集のための脂質製剤
CN116710074A (zh) * 2020-10-14 2023-09-05 乔治梅森研究基金会公司 脂质纳米颗粒制造方法和由其衍生的组合物
CN117098541A (zh) 2020-11-25 2023-11-21 阿卡格拉医药公司 用于递送核酸的脂质纳米粒及相关使用方法
CN113185421B (zh) * 2020-11-27 2022-01-25 广州市锐博生物科技有限公司 脂质化合物及其组合物
CN114315606B (zh) * 2020-12-29 2023-12-26 李斌 一种脂样分子及其应用
WO2022150717A1 (en) 2021-01-11 2022-07-14 Modernatx, Inc. Seasonal rna influenza virus vaccines
JP2024505449A (ja) 2021-01-20 2024-02-06 ビーム セラピューティクス インク． 生分解性特徴を含むナノ材料
WO2022174079A1 (en) 2021-02-12 2022-08-18 Modernatx, Inc. Lnp compositions comprising payloads for in vivo therapy
AU2022245247A1 (en) * 2021-03-24 2023-10-05 Modernatx, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
CN115515925B (zh) * 2021-04-08 2024-10-11 厦门赛诺邦格生物科技股份有限公司 一种聚乙二醇化脂质及其修饰的脂质体、含该脂质体的药物组合物及其制剂和应用
CN115197079A (zh) * 2021-04-08 2022-10-18 厦门赛诺邦格生物科技股份有限公司 一种聚乙二醇化脂质及其修饰的脂质体、含该脂质体的药物组合物及其制剂和应用
AU2022268465A1 (en) * 2021-05-06 2023-03-09 Stemirna Therapeutics Co., Ltd. A lipid
CN115385820B (zh) * 2021-05-09 2025-04-29 英维沃生物科技(苏州)有限公司 阳离子脂质及其应用
CN112979483B (zh) * 2021-05-14 2021-08-06 苏州艾博生物科技有限公司 一种阳离子脂质化合物、包含其的组合物及应用
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
CN113387825A (zh) * 2021-06-10 2021-09-14 福州大学 长链烷基酯胺类化合物或含氟长链烷基酯胺类化合物及其公斤级制备方法
AU2022291742A1 (en) * 2021-06-14 2023-12-21 Generation Bio Co. Cationic lipids and compositions thereof
CN114276535B (zh) 2021-06-30 2022-06-21 天津键凯科技有限公司 聚乙二醇脂质及其应用
KR102836820B1 (ko) * 2021-07-07 2025-07-22 포항공과대학교 산학협력단 히알루론산-지질 유도체, 이를 포함하는 지질나노입자 및 그 용도
CN119137109A (zh) * 2021-08-12 2024-12-13 生命技术公司 用于核酸递送的脂质
CN115703714B (zh) * 2021-08-13 2025-06-10 广州谷森制药有限公司 阳离子脂质化合物
CN115703713B (zh) * 2021-08-13 2025-06-10 广州谷森制药有限公司 阳离子脂质化合物
CN115710192B (zh) * 2021-08-23 2025-06-10 广州谷森制药有限公司 阳离子脂质化合物
CN115745819B (zh) * 2021-09-03 2025-06-10 广州谷森制药有限公司 阳离子脂质化合物
IL309505A (en) 2021-09-03 2024-02-01 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
CN115772089B (zh) * 2021-09-07 2025-06-10 广州谷森制药有限公司 阳离子脂质化合物
US20250027108A1 (en) 2021-10-29 2025-01-23 CureVac SE Improved circular rna for expressing therapeutic proteins
WO2023081526A1 (en) 2021-11-08 2023-05-11 Orna Therapeutics, Inc. Lipid nanoparticle compositions for delivering circular polynucleotides
KR102772764B1 (ko) 2021-11-10 2025-02-27 주식회사 에스엠엘바이오팜 트레할로즈 유도체 및 신규 구조 유지 화합물을 포함하는 핵산 의약품 전달용 지질나노입자의 약학 조성물
CN114181200B (zh) * 2021-11-24 2023-09-29 华中科技大学 一种具有高效基因转染效率的阳离子脂质体及制备与应用
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
NL2030022B1 (en) * 2021-12-03 2023-06-21 Wisdom Pharmaceutical Co Ltd SYNTHESIS OF mRNA TRANSMITTER
AR127892A1 (es) 2021-12-10 2024-03-06 Modernatx Inc Compuestos y composiciones para la administración de agentes terapéuticos
WO2023114188A1 (en) * 2021-12-14 2023-06-22 Massachusetts Institute Of Technology Ionizable lipids and compositions and uses thereof
TW202333654A (zh) 2021-12-16 2023-09-01 美商現代公司 用於製備脂質奈米顆粒之方法
CN114249662B (zh) * 2021-12-27 2024-06-21 硅羿科技（上海）有限公司 一种药用脂质体辅料alc-0315的制备方法
CN114306279A (zh) * 2021-12-30 2022-04-12 复旦大学 基于科罗索酸或其类似物的脂质纳米颗粒系统及其制备方法和应用
CN114044741B (zh) * 2022-01-13 2022-04-15 北京悦康科创医药科技股份有限公司 一种阳离子脂质化合物、包含其的组合物及用途
EP4469091A1 (en) 2022-01-28 2024-12-04 CureVac SE Nucleic acid encoded transcription factor inhibitors
EP4475882A1 (en) 2022-02-09 2024-12-18 ModernaTX, Inc. Mucosal administration methods and formulations
CN114890907B (zh) * 2022-03-31 2023-10-31 荣灿生物医药技术(上海)有限公司 一种阳离子脂质化合物及其制备方法和应用
WO2023193002A1 (en) 2022-04-01 2023-10-05 Modernatx, Inc. Cross mixers for lipid nanoparticle production, and methods of operating the same
CN114436950B (zh) * 2022-04-12 2022-09-23 凯莱英生命科学技术(天津)有限公司 使用芳基烷基氨基锂作为大位阻碱的酯基烷基化方法
CN115521220B (zh) * 2022-05-19 2023-06-09 仁景(苏州)生物科技有限公司 长链烷基酯胺类化合物及其制备方法和在核酸递送方面的应用
CN115073316B (zh) * 2022-07-26 2022-11-15 仁景(苏州)生物科技有限公司 长链烷基酯胺类脂质化合物及其制备方法和在核酸递送方面的应用
WO2023222081A1 (zh) * 2022-05-19 2023-11-23 仁景(苏州)生物科技有限公司 长链烷基酯胺类脂质化合物及其制备方法和在核酸递送方面的应用
US20250345407A1 (en) 2022-05-25 2025-11-13 CureVac SE Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
CA3256897A1 (en) 2022-05-25 2023-11-30 Akagera Medicines, Inc. Lipid nanoparticles for the administration of nucleic acids and their methods of use
WO2023236953A1 (zh) * 2022-06-06 2023-12-14 上海蓝鹊生物医药有限公司 含氮链状化合物、制备方法、包含其的组合物和应用
CN117285474A (zh) * 2022-06-16 2023-12-26 南京诺唯赞生物科技股份有限公司 一类新的脂质化合物及其用途
CN114773217B (zh) * 2022-06-20 2022-10-18 深圳市瑞吉生物科技有限公司 用于递送核酸的阳离子脂质化合物和组合物及用途
US12297285B2 (en) 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
CN117417264B (zh) * 2022-07-19 2025-12-16 深圳深信生物科技有限公司 氨基脂质化合物、其制备方法和应用
WO2024019936A1 (en) 2022-07-20 2024-01-25 Beam Therapeutics Inc. Nanomaterials comprising triols
WO2024031051A1 (en) * 2022-08-05 2024-02-08 Life Technologies Corporation Lipids for nucleic acid delivery
WO2024032613A1 (zh) * 2022-08-09 2024-02-15 斯微(上海)生物科技股份有限公司 一种脂质组合物
CN115232128B (zh) * 2022-08-15 2024-03-29 中国科学技术大学 一种咪唑并吡啶基脂质化合物及其制备方法与应用
GB202213166D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
WO2024051825A1 (zh) * 2022-09-09 2024-03-14 厦门赛诺邦格生物科技股份有限公司 一种碳核阳离子脂质
KR20250073120A (ko) 2022-09-19 2025-05-27 쑤저우 선카디아 바이오파마수티컬즈 컴퍼니 리미티드 2-히드록시에틸 아미노카프로에이트계 화합물을 제조하는 방법 및 이의 용도
US12186389B2 (en) 2022-10-28 2025-01-07 Glaxosmithkline Biologicals Sa Nucleic acid base vaccine against emerging SARS-CoV-2 variants
WO2024098361A1 (zh) * 2022-11-11 2024-05-16 斯微(上海)生物科技股份有限公司 人工核酸分子
AU2023382586A1 (en) * 2022-11-16 2025-05-22 Samyang Holdings Corporation Cationic lipids and method for preparing same
CN115487306B (zh) * 2022-11-18 2023-03-17 深圳市华元生物技术股份有限公司 一种药物递送载体及其制备方法、应用、糖尿病治疗药物
CN120225500A (zh) * 2022-11-18 2025-06-27 韩国生命工学研究院 用于活性物质递送的脂质化合物及组合物
EP4630397A1 (en) 2022-12-08 2025-10-15 ModernaTX, Inc. Ionizable lipids with malonate tails
KR20240088561A (ko) 2022-12-12 2024-06-20 한국과학기술연구원 신규한 지질 화합물 및 이를 포함하는 지질 나노입자 조성물
EP4644361A1 (en) * 2022-12-29 2025-11-05 SurgiNex Co., Ltd. Lipid nanoparticle formulation comprising ionized lipids with branched structure, and use thereof
CN116375592B (zh) * 2023-01-05 2025-05-16 北京悦康科创医药科技股份有限公司 长效低毒的新型阳离子脂质化合物及其组合物
CN116178193B (zh) * 2023-01-05 2023-07-28 北京悦康科创医药科技股份有限公司 高效低毒且稳定性表达的阳离子脂质化合物及其组合物
CN115784921B (zh) 2023-02-08 2023-05-05 北京悦康科创医药科技股份有限公司 肝外靶向高效低毒的阳离子脂质化合物及其组合物
DE112024001143T5 (de) 2023-03-08 2025-12-18 CureVac SE Neue lipid-nanopartikel-formeln für die abgabe von nukleinsäuren
WO2024197310A1 (en) 2023-03-23 2024-09-26 Modernatx, Inc. Peg targeting compounds for delivery of therapeutics
WO2024197309A1 (en) 2023-03-23 2024-09-26 Modernatx, Inc. Peg targeting compounds for delivery of therapeutics
WO2024197307A1 (en) 2023-03-23 2024-09-26 Modernatx, Inc. Peg targeting compounds for delivery of therapeutics
CN116554046B (zh) * 2023-04-17 2024-05-28 武汉滨会生物科技股份有限公司 一种可离子化脂质化合物及其脂质纳米颗粒
CN117384055B (zh) * 2023-04-27 2024-11-19 仁景(苏州)生物科技有限公司 用于递送治疗剂的可电离脂质及其用途
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
CN116675624B (zh) * 2023-05-29 2025-02-14 上海耐澄生物科技有限公司 一种脂质化合物及脂质纳米颗粒
WO2024259373A1 (en) 2023-06-14 2024-12-19 Modernatx, Inc. Compounds and compositions for delivery of therapeutic agents
WO2025002352A1 (zh) * 2023-06-28 2025-01-02 上海瑞宏迪医药有限公司 一种含有阳离子脂质的药物组合物及其用途
WO2025035202A1 (en) * 2023-08-04 2025-02-20 Nanovation Therapeutics Inc. Ionizable lipids comprising macrocyclic rings for the delivery of therapeutic agents
CN119591513A (zh) * 2023-09-11 2025-03-11 苏州星核迪赛生物技术有限公司 局部递送药物的材料及其应用
CN118147134B (zh) 2023-11-06 2025-02-25 北京悦康科创医药科技股份有限公司 靶向调控PCSK9基因表达的siRNA及其应用
CN117550985B (zh) * 2023-11-08 2025-02-18 深圳厚存纳米药业有限公司 一种脂质化合物及其用途
CN117658839A (zh) * 2023-11-22 2024-03-08 武汉大学 一种含羟基可电离脂质及其制备方法与应用
CN117658840A (zh) * 2023-12-01 2024-03-08 上海现代药物制剂工程研究中心有限公司 一种可电离阳离子脂质化合物、制备方法及应用
KR20250104719A (ko) * 2023-12-29 2025-07-08 주식회사 삼양홀딩스 약물전달용 나노입자의 조성물
WO2025160381A1 (en) 2024-01-26 2025-07-31 Modernatx, Inc. Methods of preparing lipid nanoparticles
WO2025180480A1 (zh) * 2024-03-01 2025-09-04 北京剂泰医药科技有限公司 靶向肌肉的脂质纳米颗粒
CN117886711B (zh) * 2024-03-13 2024-08-06 北京新合睿恩生物医疗科技有限公司 一种阳离子脂质化合物及其制备方法和应用、及lnp组合物
CN119264001A (zh) * 2024-04-03 2025-01-07 上海蓝鹊生物医药有限公司 含氮链状化合物、制备方法、包含其的组合物和应用
WO2025217121A1 (en) * 2024-04-08 2025-10-16 Popvax Private Limited Novel lipids for delivery of nucleic acid therapeutics
CN118388360B (zh) * 2024-04-17 2025-04-04 北京悦康科创医药科技股份有限公司 含有苯环结构的长效脾靶向阳离子脂质化合物、包含其的组合物及用途
CN118240844B (zh) 2024-05-27 2024-12-13 北京悦康科创医药科技股份有限公司 带状疱疹mRNA疫苗及其制备方法和应用
CN120483890B (zh) * 2025-07-16 2025-10-21 北京悦康科创医药科技股份有限公司 多叔胺多尾链可电离阳离子脂质、包含其的组合物及用途

Family Cites Families (367)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3324182A (en) 1962-12-26 1967-06-06 Monsanto Res Corp Penta-alkyldialkylenetriamines
US3872171A (en) 1971-05-24 1975-03-18 Pfizer Polyamines as antiviral agents in animals
US3799876A (en) 1970-12-11 1974-03-26 Texaco Inc Corrosion inhibiting lubrication method
US4125544A (en) 1977-06-09 1978-11-14 G. D. Searle 20/22/23/24-Oxa-7-oxocholesterols and esters thereof
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
ES2200016T3 (es) 1989-03-21 2004-03-01 Vical Incorporated Expresion de secuencias polinucleotidicas exogenas en un vertebrado.
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
FR2676072B1 (fr) 1991-05-03 1994-11-18 Transgene Sa Vecteur de delivrance d'arn.
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
JPH07503372A (ja) 1992-01-23 1995-04-13 バイカル・インコーポレイテッド 生体外遺伝子導入
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5807861A (en) 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US7288266B2 (en) 1996-08-19 2007-10-30 United States Of America As Represented By The Secretary, Department Of Health And Human Services Liposome complexes for increased systemic delivery
US6143276A (en) 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
WO1999014346A2 (en) 1997-09-19 1999-03-25 Sequitur, Inc. SENSE mRNA THERAPY
US6673192B1 (en) 1997-09-25 2004-01-06 Loctite Corporation Multi-amine compound primers for bonding of polyolefins with cyanoacrylate adhesives
CA2348675A1 (en) 1997-10-24 1999-05-06 Warren Dang Methods for preparing polynucleotide transfection complexes
JP2001521759A (ja) 1997-11-12 2001-11-13 ザ ブリガム アンド ウィメンズ ホスピタル，インコーポレイテッド ヒトアミロイド前駆体タンパク質遺伝子の翻訳エンハンサーエレメント
ATE243045T1 (de) 1997-11-20 2003-07-15 Vical Inc Behandlung von krebs durch verwendung von zytokin-exprimierender polynukleotiden und zusammensetzungen dafür
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US6432925B1 (en) 1998-04-16 2002-08-13 John Wayne Cancer Institute RNA cancer vaccine and methods for its use
GB9808268D0 (en) 1998-04-17 1998-06-17 Imp College Innovations Ltd Compound
US6395253B2 (en) 1998-04-23 2002-05-28 The Regents Of The University Of Michigan Microspheres containing condensed polyanionic bioactive agents and methods for their production
JP2000169864A (ja) 1998-12-07 2000-06-20 New Japan Chem Co Ltd 模型エンジン用燃料組成物
ATE297190T1 (de) 1999-02-26 2005-06-15 Chiron Corp Mikroemulsionen mit adsorbierten makromolekülen und mikropartikeln
AU7725500A (en) 1999-09-30 2001-04-30 National Jewish Medical And Research Center Method for inhibition of pathogenic microorganisms
US7060291B1 (en) 1999-11-24 2006-06-13 Transave, Inc. Modular targeted liposomal delivery system
EP1259602A1 (en) 2000-01-28 2002-11-27 The Scripps Research Institute Methods of identifying synthetic transcriptional and translational regulatory elements, and compositions relating to same
US7468275B2 (en) 2000-01-28 2008-12-23 The Scripps Research Institute Synthetic internal ribosome entry sites and methods of identifying same
US20040142474A1 (en) 2000-09-14 2004-07-22 Expression Genetics, Inc. Novel cationic lipopolymer as a biocompatible gene delivery agent
US6696038B1 (en) 2000-09-14 2004-02-24 Expression Genetics, Inc. Cationic lipopolymer as biocompatible gene delivery agent
US7708915B2 (en) 2004-05-06 2010-05-04 Castor Trevor P Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
DE10109897A1 (de) 2001-02-21 2002-11-07 Novosom Ag Fakultativ kationische Liposomen und Verwendung dieser
EP1404860B8 (en) 2001-05-30 2013-12-25 The Scripps Research Institute Delivery system for nucleic acids
EP1800697B1 (de) 2001-06-05 2010-04-14 CureVac GmbH Stabilisierte mRNA mit erhöhtem G/C-Gehalt für die Gentherapie
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
DE10207178A1 (de) 2002-02-19 2003-09-04 Novosom Ag Komponenten für die Herstellung amphoterer Liposomen
US20050222064A1 (en) 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
AU2003221497A1 (en) 2002-03-13 2003-09-22 Novartis Ag Pharmaceutical microparticles
EP1499187B1 (en) 2002-04-04 2015-06-17 Zoetis Belgium S.A. Immunostimulatory g,u-containing oligoribonucleotides
EP2338478B1 (en) 2002-06-28 2014-07-23 Protiva Biotherapeutics Inc. Method for producing liposomes
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
DE10335833A1 (de) 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
AU2004280143A1 (en) 2003-10-11 2005-04-21 Tekmira Pharmaceuticals Corporation Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
US7927873B2 (en) 2003-12-19 2011-04-19 University Of Cincinnati Polyamides for nucleic acid delivery
US7745651B2 (en) 2004-06-07 2010-06-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
AU2005252273B2 (en) 2004-06-07 2011-04-28 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
WO2006005058A2 (en) 2004-06-30 2006-01-12 Nektar Therapeutics Al, Corporation Polymer-factor ix moiety conjugates
DE102004042546A1 (de) 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
US8663599B1 (en) 2004-10-05 2014-03-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
CA2590098C (en) 2004-12-10 2015-03-31 Justin Hanes Functionalized poly (ether-anhydride) block copolymers
DE102005023170A1 (de) 2005-05-19 2006-11-23 Curevac Gmbh Optimierte Formulierung für mRNA
EP2476756A1 (en) 2005-06-15 2012-07-18 Massachusetts Institute of Technology Amine-containing lipids and uses thereof
EP2479254A1 (en) 2005-08-24 2012-07-25 The Scripps Research Institute Translation enhancer-element dependent vector systems
DE102006007433A1 (de) 2006-02-17 2007-08-23 Curevac Gmbh Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure
US8231907B2 (en) 2006-03-21 2012-07-31 Morehouse School Of Medicine Nanoparticles for delivery of active agents
JP2009534309A (ja) 2006-03-31 2009-09-24 マサチューセッツ インスティテュート オブ テクノロジー 治療剤の標的化送達のためのシステム
EP2019691B1 (en) 2006-05-15 2020-08-12 Massachusetts Institute of Technology Polymers for functional particles
WO2008013785A2 (en) 2006-07-24 2008-01-31 Singh-Broemer And Company, Inc. Solid nanoparticle formulation of water insoluble pharmaceutical substances with reduced ostwald ripening
CA2659301A1 (en) 2006-07-28 2008-02-07 Applera Corporation Dinucleotide mrna cap analogs
JP2010507361A (ja) 2006-07-31 2010-03-11 キュアバック ゲーエムベーハー 具体的には免疫刺激剤／アジュバントとしての、一般式（Ｉ）：ＧｌＸｍＧｎ、または一般式（ＩＩ）：ＣｌＸｍＣｎで表される核酸
CN105030654A (zh) 2006-10-03 2015-11-11 阿尔尼拉姆医药品有限公司 含脂质的制品
CA2665343C (en) 2006-10-05 2014-12-16 The Johns Hopkins University Water-dispersible oral, parenteral, and topical formulations for poorly water soluble drugs using smart polymeric nanoparticles
DE102006051516A1 (de) 2006-10-31 2008-05-08 Curevac Gmbh (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
DE102006061015A1 (de) 2006-12-22 2008-06-26 Curevac Gmbh Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
JP5249248B2 (ja) 2007-03-05 2013-07-31 ワシントン ユニバーシティー 膜組み込みペプチドのためのナノ粒子輸送システム
WO2008127688A1 (en) 2007-04-13 2008-10-23 Hart Communication Foundation Synchronizing timeslots in a wireless communication protocol
WO2008135855A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
AU2008247488B2 (en) 2007-05-04 2014-02-27 Marina Biotech, Inc. Amino acid lipids and uses thereof
US20090042825A1 (en) 2007-08-06 2009-02-12 Majed Matar Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer
US9144546B2 (en) 2007-08-06 2015-09-29 Clsn Laboratories, Inc. Nucleic acid-lipopolymer compositions
WO2009024599A1 (en) 2007-08-23 2009-02-26 Novartis Ag Methods for detecting oligonucleotides
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
CA2891005A1 (en) 2007-09-28 2008-10-09 Bind Therapeutics, Inc. Cancer cell targeting using nanoparticles
CA2917512C (en) 2007-10-12 2025-08-05 President And Fellows Of Harvard College VACCINE NANOTECHNOLOGY
TW200927915A (en) 2007-10-25 2009-07-01 Croda Int Plc Laundry formulations and method of cleaning
SG10201408165WA (en) 2007-12-11 2015-01-29 Scripps Research Inst Compositions and methods related to mrna translational enhancer elements
EP3100718B1 (en) 2008-01-02 2019-11-27 Arbutus Biopharma Corporation Improved compositions and methods for the delivery of nucleic acids
HRP20150528T2 (hr) 2008-01-31 2016-03-25 Curevac Gmbh NUKLEINSKE KISELINE KOJE SADRŽE FORMULU (NuGiXmGnNv)a TE NJIHOVI DERIVATI KAO IMUNOSTIMULACIJSKA SREDSTVA/POMOĆNA SREDSTVA
JP5475753B2 (ja) 2008-04-15 2014-04-16 プロチバ バイオセラピューティクス インコーポレイティッド 核酸送達用の脂質製剤
WO2009129395A1 (en) 2008-04-16 2009-10-22 Abbott Laboratories Cationic lipids and uses thereof
WO2009129385A1 (en) 2008-04-16 2009-10-22 Abbott Laboratories Cationic lipids and uses thereof
WO2009127230A1 (en) 2008-04-16 2009-10-22 Curevac Gmbh MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
WO2009131704A2 (en) 2008-04-25 2009-10-29 Northwestern University Nanostructures suitable for sequestering cholesterol and other molecules
US8697098B2 (en) 2011-02-25 2014-04-15 South Dakota State University Polymer conjugated protein micelles
PL215513B1 (pl) 2008-06-06 2013-12-31 Univ Warszawski Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
WO2010005726A2 (en) 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
EP2309990B2 (en) 2008-06-16 2017-03-15 Pfizer Inc. Drug loaded polymeric nanoparticles and methods of making and using same
EP2285350B1 (en) 2008-06-16 2017-11-15 Pfizer Inc Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic nanoparticles
US20100063135A1 (en) 2008-09-10 2010-03-11 Abbott Laboratories Polyethylene glycol lipid conjugates and uses thereof
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
EP3225621A1 (en) 2008-10-09 2017-10-04 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
CN104910025B (zh) 2008-11-07 2019-07-16 麻省理工学院 氨基醇类脂质和其用途
MX338780B (es) 2008-11-10 2016-05-02 Alnylam Pharmaceuticals Inc Lipidos y composiciones novedosas para el suministro de terapeuticos.
CA2780482A1 (en) 2008-11-17 2010-05-10 Anil K. Sood Hdl particles for delivery of nucleic acids
WO2010060818A1 (de) 2008-11-25 2010-06-03 Basf Se Alkoxylierte oligo- oder polyamine als oxidationsstabilisatoren
US8563041B2 (en) 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
JP2012512175A (ja) 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド 治療薬を徐放するための長時間循環性ナノ粒子
EP3243504A1 (en) 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Improved lipid formulation
WO2010088927A1 (en) 2009-02-09 2010-08-12 Curevac Gmbh Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds
US20140141089A1 (en) 2009-02-11 2014-05-22 Colorado School Of Mines Nanoparticles, Compositions Thereof, and Methods of Use, and Methods of Making the Same
CN102438978B (zh) 2009-03-20 2017-02-22 Clsn实验室股份有限公司 聚胺衍生物
US8715736B2 (en) 2009-04-30 2014-05-06 Florida Agricultural And Mechanical University Nanoparticle formulations for skin delivery
WO2010127159A2 (en) 2009-04-30 2010-11-04 Intezyne Technologies, Incorporated Polymeric micelles for polynucleotide encapsulation
EP3097908A1 (en) 2009-05-05 2016-11-30 Arbutus Biopharma Corporation Lipid compositions
CA2760706C (en) 2009-05-05 2019-08-06 Alnylam Pharmaceuticals, Inc. Methods of delivering oligonucleotides to immune cells
US9080186B2 (en) 2009-05-16 2015-07-14 Agave Pharma, Incorporated Compositions comprising cationic amphiphiles and colipids for delivering therapeutic molecules
PL2440183T3 (pl) 2009-06-10 2019-01-31 Arbutus Biopharma Corporation Ulepszona formulacja lipidowa
NZ597504A (en) 2009-06-15 2013-10-25 Alnylam Pharmaceuticals Inc Lipid formulated dsrna targeting the pcsk9 gene
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
CA2767127A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
WO2011017548A1 (en) 2009-08-05 2011-02-10 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
US8449916B1 (en) 2009-11-06 2013-05-28 Iowa State University Research Foundation, Inc. Antimicrobial compositions and methods
PH12012500929A1 (en) 2009-11-12 2012-11-26 Kao Corp Method for producing olefins
EP3318248B1 (en) 2009-12-01 2019-04-10 Translate Bio, Inc. Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
EP3296398A1 (en) 2009-12-07 2018-03-21 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
EP2509634B1 (en) 2009-12-11 2019-03-06 Pfizer Inc Stable formulations for lyophilizing therapeutic particles
EP3494963A1 (en) 2009-12-18 2019-06-12 The University of British Columbia Methods and compositions for delivery of nucleic acids
WO2011076807A2 (en) 2009-12-23 2011-06-30 Novartis Ag Lipids, lipid compositions, and methods of using them
US9149432B2 (en) 2010-03-19 2015-10-06 Massachusetts Institute Of Technology Lipid vesicle compositions and methods of use
WO2011119262A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc. Methods and systems for generating nanoparticles
EP2558074B1 (en) 2010-04-08 2018-06-06 The Trustees of Princeton University Preparation of lipid nanoparticles
CN104959052B (zh) 2010-04-09 2018-07-13 帕西拉制药有限公司 用于配制大直径合成膜囊泡的方法
US9408914B2 (en) 2010-04-28 2016-08-09 Kyowa Hakko Kirin Co., Ltd. Cationic lipid
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
WO2011143230A1 (en) 2010-05-10 2011-11-17 Alnylam Pharmaceuticals Methods and compositions for delivery of active agents
WO2011141704A1 (en) 2010-05-12 2011-11-17 Protiva Biotherapeutics, Inc Novel cyclic cationic lipids and methods of use
EP2569276B1 (en) 2010-05-12 2021-02-24 Arbutus Biopharma Corporation Novel cationic lipids and methods of use thereof
EP2387999A1 (en) 2010-05-21 2011-11-23 CureVac GmbH Histidine-containing solution for transfection and/or injection of nucleic acids and uses thereof
JP2013531634A (ja) 2010-05-24 2013-08-08 メルク・シャープ・エンド・ドーム・コーポレイション オリゴヌクレオチド送達のための新規なアミノアルコールカチオン性脂質
US8748667B2 (en) 2010-06-04 2014-06-10 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
WO2012002760A2 (ko) 2010-07-01 2012-01-05 포항공과대학교 산학협력단 세균유래 마이크로베시클을 이용한 암치료 및 암진단 방법
CA2804396C (en) 2010-07-06 2021-06-29 Novartis Ag Liposomes with lipids having an advantageous pka-value for rna delivery
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
US11291635B2 (en) 2010-07-06 2022-04-05 Glaxosmithkline Biological Sa Virion-like delivery particles for self-replicating RNA molecules
US20130230884A1 (en) 2010-07-16 2013-09-05 John Chaput Methods to Identify Synthetic and Natural RNA Elements that Enhance Protein Translation
EP2449113B8 (en) 2010-07-30 2015-11-25 CureVac AG Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
WO2012024595A2 (en) 2010-08-20 2012-02-23 University Of Washington Circumferential aerosol device for delivering drugs to olfactory epithelium and brain
SI3981427T1 (sl) 2010-08-31 2022-08-31 Glaxosmithkline Biologicals S.A. Pegilirani liposomi za dostavo imunogen-kodirajoče RNA
US20130189351A1 (en) 2010-08-31 2013-07-25 Novartis Ag Lipids suitable for liposomal delivery of protein coding rna
RS63890B1 (sr) 2010-08-31 2023-02-28 Glaxosmithkline Biologicals Sa Mali lipozomi za isporuku rnk koja kodira imunogen
US9549901B2 (en) 2010-09-03 2017-01-24 The Brigham And Women's Hospital, Inc. Lipid-polymer hybrid particles
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
ES2888231T3 (es) 2010-09-20 2022-01-03 Sirna Therapeutics Inc Lípidos catiónicos de bajo peso molecular para el suministro de oligonucleótidos
EP2618821A4 (en) 2010-09-24 2014-08-13 Brigham & Womens Hospital NANOSTRUCTURED GELS FOR CONTROLLED RELEASE OF CAPSUED MEDIUM
EP2621480B1 (en) 2010-09-30 2018-08-15 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
EP3485913A1 (en) 2010-10-21 2019-05-22 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
WO2012068176A1 (en) 2010-11-15 2012-05-24 Life Technologies Corporation Amine-containing transfection reagents and methods for making and using same
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
CN102068701B (zh) 2011-01-18 2012-11-07 沈阳药科大学 可断裂peg脂质衍生物在制剂中的应用
US20140065172A1 (en) 2011-01-26 2014-03-06 Cenix Bioscience Gmbh Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
US10363309B2 (en) 2011-02-04 2019-07-30 Case Western Reserve University Targeted nanoparticle conjugates
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
AU2012217685B2 (en) 2011-02-15 2017-05-18 Merrimack Pharmaceuticals, Inc. Compositions and methods for delivering nucleic acid to a cell
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
CN102204920B (zh) 2011-03-18 2013-03-20 海南本创医药科技有限公司 阿司匹林钠普伐他汀钠药物组合物固体制剂
ES2785108T3 (es) 2011-03-24 2020-10-05 Glaxosmithkline Biologicals Sa Nanoemulsiones adyuvantes con fosfolípidos
WO2012142132A1 (en) 2011-04-11 2012-10-18 Life Technologies Corporation Polymer particles and methods of making and using same
WO2013158127A1 (en) 2012-04-16 2013-10-24 Molecular Transfer, Inc. Agents for improved delivery of nucleic acids to eukaryotic cells
EP2701686A4 (en) 2011-04-28 2014-11-05 Stc Unm LIPID BINCHES SUPPORTED ON POROUS NANOPARTICLES (PROTOCELLS) FOR TARGETED ADMINISTRATION, AND METHODS OF USE THEREOF
CN104623666A (zh) 2011-04-29 2015-05-20 西莱克塔生物科技公司 用于诱导调节性b细胞的致耐受性合成纳米载体
AU2012254842A1 (en) 2011-05-12 2013-05-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Liposomes comprising polymer-conjugated lipids and related uses
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
CN107115314B (zh) 2011-06-02 2022-04-29 加利福尼亚大学董事会 膜包封的纳米颗粒及使用方法
EP2717893B1 (en) 2011-06-08 2019-05-08 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mrna delivery
CA3198966A1 (en) 2011-06-08 2012-12-13 Translate Bio, Inc. Cleavable lipids
CN102813929B (zh) 2011-06-09 2014-04-09 沈阳药科大学 低浓度peg脂质衍生物及其应用
EP3854413A1 (en) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
EP2729168A2 (en) 2011-07-06 2014-05-14 Novartis AG Immunogenic compositions and uses thereof
EP3424495A1 (en) 2011-07-06 2019-01-09 GlaxoSmithKline Biologicals S.A. Oil-in-water emulsions that contain nucleic acids
BR112014000236A2 (pt) 2011-07-06 2017-02-14 Novartis Ag lipossomas com razão n:p útil para a liberação de moléculas de rna, composição e uso de ditos lipossomas
CA2840965C (en) 2011-07-06 2021-03-02 Novartis Ag Cationic oil-in-water emulsions
WO2013016058A1 (en) 2011-07-22 2013-01-31 Merck Sharp & Dohme Corp. Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery
US8889657B2 (en) 2011-08-31 2014-11-18 Mallinckrodt Llc Nanoparticle PEG modification with H-phosphonates
HUE041800T2 (hu) 2011-08-31 2019-05-28 Glaxosmithkline Biologicals Sa Pegilált liposzómák immunogént kódoló RNS bejuttatására
US9126966B2 (en) 2011-08-31 2015-09-08 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use thereof
SMT202300232T1 (it) 2011-09-08 2023-09-06 Sage Therapeutics Inc Steroidi neuroattivi, composizioni e relativi usi
US9375388B2 (en) 2011-09-23 2016-06-28 Indian Institute Of Technology, Bombay Nanoparticle based cosmetic composition
WO2013049328A1 (en) 2011-09-27 2013-04-04 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted pegylated lipids
BR112014008932A2 (pt) 2011-10-14 2019-09-24 Sandia Corp bicamadas lipídicas suportadas em nanopartículas porosas (protocélulas) para administração direcionada, incluindo a administração transdérmica de uma carga e métodos associados
DK2768958T3 (da) 2011-10-18 2019-09-16 Dicerna Pharmaceuticals Inc Kationiske aminlipider og anvendelser deraf
CA2852857A1 (en) 2011-10-20 2013-04-25 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
JP2015502337A (ja) 2011-10-25 2015-01-22 ザ ユニバーシティ オブ ブリティッシュ コロンビア 限界サイズ脂質ナノ粒子および関連方法
CA2852564A1 (en) 2011-10-31 2013-05-10 Mallinckrodt Llc Combinational liposome compositions for cancer therapy
US9579338B2 (en) 2011-11-04 2017-02-28 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
EP3673898A1 (en) 2011-11-04 2020-07-01 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
US9872870B2 (en) 2011-11-04 2018-01-23 University Of Notre Dame Du Lac Multifunctional micellar nanoparticle-based drug and targeting agent system
EP2776013B8 (en) 2011-11-08 2023-08-30 The Board of Trustees of the University of Arkansas Methods and compositions for x-ray induced release from ph sensitive liposomes
WO2013082470A1 (en) 2011-12-02 2013-06-06 Pegasus Laboratories, Inc. Amphipathic lipid-based sustained release compositions
CA2856737C (en) 2011-12-07 2023-09-26 Alnylam Pharmaceuticals, Inc. Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
WO2013086373A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
EP2788006A1 (en) 2011-12-07 2014-10-15 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
EP2787977A4 (en) 2011-12-09 2015-05-06 Univ California LIPOSOMAL ACTIVE INVERTING
TWI594767B (zh) 2011-12-12 2017-08-11 協和醱酵麒麟有限公司 含有陽離子性脂質之藥物傳遞系統用脂質奈米粒子
CN104159615B (zh) * 2011-12-12 2017-08-18 协和发酵麒麟株式会社 含有阳离子性脂质的组合的脂质纳米粒子
EP2604253A1 (en) 2011-12-13 2013-06-19 Otto Glatter Water-in-oil emulsions and methods for their preparation
US9636414B2 (en) 2011-12-15 2017-05-02 Biontech Ag Particles comprising single stranded RNA and double stranded RNA for immunomodulation
AU2012352180A1 (en) 2011-12-16 2014-07-31 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
WO2013103659A1 (en) 2012-01-04 2013-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Stabilizing rna by incorporating chain-terminating nucleosides at the 3'-terminus
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
WO2013113325A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Negatively charged nucleic acid comprising complexes for immunostimulation
EP2623121A1 (en) 2012-01-31 2013-08-07 Bayer Innovation GmbH Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
CN104245745B (zh) 2012-02-09 2017-03-29 生命技术公司 亲水性聚合物颗粒及其制备方法
WO2013120498A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
WO2013120500A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
HK1205751A1 (en) 2012-02-22 2015-12-24 Cerulean Pharma Inc. Conjugates, particles, compositions, and related methods
US20130243867A1 (en) 2012-02-23 2013-09-19 University Of South Florida (A Florida Non-Profit Corporation) Micelle compositions and methods for their use
AU2013222179B2 (en) 2012-02-24 2017-08-24 Arbutus Biopharma Corporat ion Trialkyl cationic lipids and methods of use thereof
US10322089B2 (en) 2012-03-14 2019-06-18 The Board Of Trustees Of The Leland Stanford Junior University Nanoparticles, nanoparticle delivery methods, and systems of delivery
DK2825156T3 (en) 2012-03-16 2017-10-30 Merck Patent Gmbh TARGETED AMINO ACID LIPIDS
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
EP2830991A1 (en) 2012-03-26 2015-02-04 President and Fellows of Harvard College Lipid-coated nucleic acid nanostructures of defined shape
EP2831239B1 (en) 2012-03-27 2017-11-22 CureVac AG Artificial nucleic acid molecules
DK2830594T3 (en) 2012-03-27 2018-08-13 Sirna Therapeutics Inc DIETHER-BASED BIOLOGICALLY DEGRADABLE CATIONIC LIPIDS FOR siRNA RELEASE
RU2750261C2 (ru) 2012-03-27 2021-06-25 Кьюрвак Аг Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков и пептидов
RU2660565C2 (ru) 2012-03-27 2018-07-06 Кьюрвак Аг Молекулы искусственной нуклеиновой кислоты, содержащие 5'utr гена top
HK1206644A1 (en) 2012-03-29 2016-01-15 Shire Human Genetic Therapies, Inc. Lipid-derived neutral nanoparticles
US20150064115A1 (en) 2012-04-05 2015-03-05 University Of Florida Research Foundation, Inc. Neurophilic nanoparticles
EP2836234B1 (en) 2012-04-12 2019-06-12 Yale University Vehicles for controlled delivery of different pharmaceutical agents
CA2870941C (en) 2012-04-19 2021-05-25 Sirna Therapeutics, Inc. Diester and triester based low molecular weight, biodegradable cationic lipids for oligonucleotide delivery
WO2013163234A1 (en) 2012-04-23 2013-10-31 Massachusetts Institute Of Technology Stable layer-by-layer coated particles
WO2013166498A1 (en) 2012-05-04 2013-11-07 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
WO2013173693A1 (en) 2012-05-18 2013-11-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nanoparticles with enhanced entry into cancer cells
CA2874495A1 (en) 2012-05-23 2013-11-28 The Ohio State University Lipid-coated albumin nanoparticle compositions and methods of making and methods of using the same
US20150306249A1 (en) 2012-05-25 2015-10-29 Curevac Gmbh Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings
WO2013185069A1 (en) 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Pulmonary delivery of mrna to non-lung target cells
CA2876148C (en) 2012-06-08 2021-01-12 Nitto Denko Corporation Lipids for therapeutic agent delivery formulations
US9415109B2 (en) 2012-07-06 2016-08-16 Alnylam Pharmaceuticals, Inc. Stable non-aggregating nucleic acid lipid particle formulations
TW201408625A (zh) * 2012-07-06 2014-03-01 Kyowa Hakko Kirin Co Ltd 陽離子性脂質
US9956291B2 (en) 2012-07-10 2018-05-01 Shaker A. Mousa Nanoformulation and methods of use of thyroid receptor beta1 agonists for liver targeting
CA2884870C (en) 2012-08-13 2022-03-29 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
US9775804B2 (en) 2012-08-14 2017-10-03 Aaron Froese Internal structured self assembling liposomes
WO2014028763A1 (en) 2012-08-15 2014-02-20 The University Of Chicago Exosome-based therapeutics against neurodegenerative disorders
WO2014047649A1 (en) 2012-09-24 2014-03-27 The Regents Of The University Of California Methods for arranging and packing nucleic acids for unusual resistance to nucleases and targeted delivery for gene therapy
US20150246137A1 (en) 2012-09-27 2015-09-03 The University Of North Carolina At Chapel Hill Lipid coated nanoparticles containing agents having low aqueous and lipid solubilities and methods thereof
EP2900681B1 (en) 2012-09-28 2019-07-10 Ionovation GmbH Pharmaceutical composition comprising lipophilic nucleosides
EP2903595A1 (en) 2012-10-04 2015-08-12 University Of The Witwatersrand, Johannesburg Liposomal drug delivery system
WO2014071072A2 (en) 2012-11-02 2014-05-08 Pungente Michael D Novel cationic carotenoid-based lipids for cellular nucleic acid uptake
US9669104B2 (en) 2012-11-07 2017-06-06 Council Of Scientific And Industrial Research Nanocomplex containing amphipathic peptide useful for efficient transfection of biomolecules
ES2968649T3 (es) 2012-12-07 2024-05-13 Translate Bio Inc Nanopartículas lipídicas para la administración de ARNm en los pulmones
SG10201710472PA (en) 2013-02-22 2018-02-27 Curevac Ag Combination of vaccination and inhibition of the pd-1 pathway
WO2014160243A1 (en) 2013-03-14 2014-10-02 The Trustees Of The University Of Pennsylvania Purification and purity assessment of rna molecules synthesized with modified nucleosides
DK2972360T3 (en) 2013-03-15 2018-05-22 Translate Bio Inc SYNERGISTIC IMPROVEMENT OF DELIVERY OF NUCLEIC ACIDS THROUGH MIXED FORMULATIONS
CA2906732C (en) 2013-03-15 2023-08-08 The University Of British Columbia Lipid nanoparticles for transfection and related methods
TW201515650A (zh) 2013-05-06 2015-05-01 艾爾妮蘭製藥公司 遞送經脂質調配之核酸分子之劑量及方法
US9895443B2 (en) 2013-06-26 2018-02-20 Massachusetts Institute Of Technology Multi-tailed lipids and uses thereof
WO2015002667A1 (en) 2013-07-01 2015-01-08 Myq, Inc. A location regulated point-of-sale system and enhancements
WO2015011633A1 (en) 2013-07-23 2015-01-29 Protiva Biotherapeutics, Inc. Compositions and methods for delivering messenger rna
WO2015024667A1 (en) 2013-08-21 2015-02-26 Curevac Gmbh Method for increasing expression of rna-encoded proteins
MX2016002153A (es) 2013-08-21 2017-03-01 Curevac Ag Composicion y vacuna para tratar cancer de prostata.
RU2712743C2 (ru) 2013-08-21 2020-01-30 Куревак Аг Вакцина против бешенства
CN105473157A (zh) 2013-08-21 2016-04-06 库瑞瓦格股份公司 组合疫苗
WO2015024666A1 (en) 2013-08-21 2015-02-26 Curevac Gmbh Composition and vaccine for treating lung cancer
CA2915728A1 (en) 2013-08-21 2015-02-26 Thomas Kramps Respiratory syncytial virus (rsv) vaccine
CA2925021C (en) 2013-11-01 2025-05-06 Curevac Ag MODIFIED MESSENGER RIBONUCLE ACID (MRNA) WITH REDUCED IMMUNOSTIMULATING PROPERTIES
US9365610B2 (en) 2013-11-18 2016-06-14 Arcturus Therapeutics, Inc. Asymmetric ionizable cationic lipid for RNA delivery
EP4019506A1 (en) 2013-12-19 2022-06-29 Novartis AG Lipids and lipid compositions for the delivery of active agents
JP6584414B2 (ja) 2013-12-30 2019-10-02 キュアバック アーゲー 人工核酸分子
AU2014375402B2 (en) 2013-12-30 2020-10-01 CureVac SE Artificial nucleic acid molecules
WO2015101416A1 (en) 2013-12-30 2015-07-09 Curevac Gmbh Methods for rna analysis
WO2015130584A2 (en) 2014-02-25 2015-09-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
WO2015154002A1 (en) 2014-04-04 2015-10-08 Ohio State Innovation Foundation Oligonucleotide lipid nanoparticle compositions, methods of making and methods of using the same
CN106795096B (zh) 2014-06-25 2020-05-29 爱康泰生治疗公司 用于递送核酸的新型脂质和脂质纳米颗粒制剂
WO2016004202A1 (en) 2014-07-02 2016-01-07 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
BR112016030852A2 (pt) 2014-07-02 2018-01-16 Shire Human Genetic Therapies encapsulação de rna mensageiro
CN104644555A (zh) 2014-11-18 2015-05-27 中国科学院过程工程研究所 一种避免加速血液清除现象的长循环脂质体、制备方法及应用
CN114642735A (zh) 2015-01-21 2022-06-21 菲泽尔克斯公司 用于将治疗剂和诊断剂递送到细胞中的方法、组合物和系统
EP3247363A4 (en) 2015-01-21 2018-10-03 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
EP3289083A4 (en) * 2015-04-27 2018-12-19 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
HRP20240865T1 (hr) 2015-06-29 2024-10-11 Acuitas Therapeutics Inc. Lipidi i formulacije lipidnih nanočestica za isporuku nukleinskih kiselina
EP3325505B1 (en) 2015-07-23 2020-08-19 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
ES2910425T3 (es) 2015-09-17 2022-05-12 Modernatx Inc Compuestos y composiciones para la administración intracelular de agentes terapéuticos
MD3718565T2 (ro) 2015-10-22 2022-09-30 Modernatx Inc Vaccinuri împotriva virusului respirator
US20180289792A1 (en) 2015-10-22 2018-10-11 ModernaTX. Inc. Sexually transmitted disease vaccines
AU2016343803B2 (en) 2015-10-28 2021-04-29 Acuitas Therapeutics, Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
AU2016366978B2 (en) * 2015-12-10 2022-07-28 Modernatx, Inc. Compositions and methods for delivery of therapeutic agents
WO2017100744A1 (en) 2015-12-11 2017-06-15 Preceres Inc. Aminolipidoids and uses thereof
JP7065036B2 (ja) 2015-12-17 2022-05-11 モダーナティエックス・インコーポレイテッド メチルマロニルＣｏＡムターゼをコードするポリヌクレオチド
SMT202200252T1 (it) 2015-12-22 2022-07-21 Modernatx Inc Composti e composizioni per il rilascio intracellulare di agenti
US20190022247A1 (en) 2015-12-30 2019-01-24 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
US20210206818A1 (en) 2016-01-22 2021-07-08 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
US10457631B2 (en) 2016-04-06 2019-10-29 Ohio State Innovation Foundation Biodegradable amino-ester nanomaterials for nucleic acid delivery
US20190167811A1 (en) 2016-04-13 2019-06-06 Modernatx, Inc. Lipid compositions and their uses for intratumoral polynucleotide delivery
WO2017192470A1 (en) 2016-05-03 2017-11-09 Merck Sharp & Dohme Corp. Combination therapy of anti-il-10 antibody and compositions comprising lipid nanoparticles and tlr9 agonist cpg oligonucleotides
PT3458474T (pt) * 2016-05-18 2022-11-08 Modernatx Inc Combinações de arnm que codificam polipéptidos de modulação imunitária e as suas utilizações
JP2019519516A (ja) 2016-05-18 2019-07-11 モデルナティーエックス， インコーポレイテッド がんの治療のためのｍＲＮＡ併用療法
US20190298657A1 (en) 2016-05-18 2019-10-03 Modernatx, Inc. Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
JP2019519601A (ja) 2016-05-18 2019-07-11 モダーナティエックス・インコーポレイテッドＭｏｄｅｒｎａＴＸ， Ｉｎｃ． 急性間欠性ポルフィリン症の治療のためのポルホビリノゲン脱アミノ酵素をコードするポリヌクレオチド
WO2017201317A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polyribonucleotides containing reduced uracil content and uses thereof
MA45036A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polynucléotides codant pour la citrine pour le traitement de la citrullinémie de type 2
KR102533456B1 (ko) 2016-05-18 2023-05-17 모더나티엑스, 인크. 릴랙신을 인코딩하는 폴리뉴클레오타이드
WO2017201348A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
CN109195621A (zh) 2016-05-18 2019-01-11 莫得纳特斯公司 编码白细胞介素12(il12)的多核苷酸及其用途
WO2017201346A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria
MA45053A (fr) * 2016-05-18 2019-03-27 Modernatx Inc Polynucléotides codant pour un régulateur de conductance transmembranaire de fibrose kystique pour le traitement de la fibrose kystique
US12128113B2 (en) 2016-05-18 2024-10-29 Modernatx, Inc. Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
WO2017201328A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. POLYNUCLEOTIDES ENCODING α-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE
MA45050A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polynucléotides codant pour la lipoprotéine lipase destinés au traitement de l'hyperlipidémie
JP2019525901A (ja) 2016-06-14 2019-09-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 脂質ナノ粒子の安定化製剤
MX2019004913A (es) 2016-10-26 2019-09-16 Curevac Ag Vacunas de nanoparticulas lipidicas que comprenden acido ribonucleico mensajero (arnm).
EP3532103B1 (en) 2016-10-26 2025-12-03 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
US20190274968A1 (en) 2016-10-27 2019-09-12 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
EP3576780A1 (en) 2017-02-01 2019-12-11 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
CA3055653A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Lipid nanoparticle formulation
CA3056133A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Crystal forms of amino lipids
MA47787A (fr) 2017-03-15 2020-01-22 Modernatx Inc Vaccin contre le virus respiratoire syncytial
SI3596041T1 (sl) 2017-03-15 2023-02-28 Modernatx, Inc. Spojina in sestavki za intracelično dostavljanje terapevtskih sredstev
WO2018191719A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipid delivery of therapeutic agents to adipose tissue
EP4410317A3 (en) 2017-04-28 2024-10-30 Acuitas Therapeutics Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2018225871A1 (ja) 2017-06-09 2018-12-13 協和発酵キリン株式会社 カチオン性脂質としての化合物
EP3638678B1 (en) 2017-06-14 2025-12-03 ModernaTX, Inc. Compounds and compositions for intracellular delivery of agents
WO2019036008A1 (en) 2017-08-16 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
WO2019036030A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. METHODS OF MANUFACTURING LIPID NANOPARTICLES
WO2019089828A1 (en) 2017-10-31 2019-05-09 Acuitas Therapeutics, Inc. Lamellar lipid nanoparticles
WO2019152557A1 (en) 2018-01-30 2019-08-08 Modernatx, Inc. Compositions and methods for delivery of agents to immune cells
WO2019193183A2 (en) 2018-04-05 2019-10-10 Curevac Ag Novel yellow fever nucleic acid molecules for vaccination
EP4227319B1 (en) 2018-04-17 2025-11-26 CureVac SE Novel rsv rna molecules and compositions for vaccination
EP3813874A1 (en) 2018-06-27 2021-05-05 CureVac AG Novel lassa virus rna molecules and compositions for vaccination
US12263248B2 (en) 2018-09-19 2025-04-01 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
TW202039534A (zh) 2018-12-14 2020-11-01 美商美國禮來大藥廠 KRAS變體mRNA分子
KR20220103923A (ko) 2019-09-19 2022-07-25 모더나티엑스, 인크. 치료제의 세포내 전달을 위한 신규한 헤드기 지질 화합물 및 조성물
CN120423969A (zh) 2019-09-19 2025-08-05 摩登纳特斯有限公司 用于治疗剂的细胞内递送的支链尾端脂质化合物和组合物
US20220411361A1 (en) 2019-09-19 2022-12-29 Modernatx, Inc. Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents
IL297084A (en) 2020-04-09 2022-12-01 Suzhou Abogen Biosciences Co Ltd Lipid nanoparticle compounds
AU2022245247A1 (en) 2021-03-24 2023-10-05 Modernatx, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
AR127892A1 (es) 2021-12-10 2024-03-06 Modernatx Inc Compuestos y composiciones para la administración de agentes terapéuticos

Also Published As

Publication number Publication date
EP4186888A1 (en) 2023-05-31
PL3596041T3 (pl) 2023-03-06
US20190314292A1 (en) 2019-10-17
EP3596041B1 (en) 2022-11-02
AU2018234692B2 (en) 2022-06-02
JP2023021468A (ja) 2023-02-13
SG11201907916TA (en) 2019-09-27
AU2018234692A1 (en) 2019-09-19
IL298380A (en) 2023-01-01
IL268999A (en) 2019-10-31
MX2019011004A (es) 2020-08-10
WO2018170306A1 (en) 2018-09-20
US20210154148A1 (en) 2021-05-27
ES2940259T3 (es) 2023-05-04
CN110520409A (zh) 2019-11-29
HUE060693T2 (hu) 2023-04-28
JP7167049B2 (ja) 2022-11-08
JP2020514366A (ja) 2020-05-21
FI3596041T3 (fi) 2023-01-31
PT3596041T (pt) 2023-02-28
AU2022224709A1 (en) 2022-11-24
RU2019132446A3 (cg-RX-API-DMAC7.html) 2021-04-29
KR20190132405A (ko) 2019-11-27
HRP20230063T1 (hr) 2023-03-17
RU2019132446A (ru) 2021-04-15
US10857105B2 (en) 2020-12-08
US12324859B2 (en) 2025-06-10
EP4186888B1 (en) 2025-11-26
JP7596343B2 (ja) 2024-12-09
IL268999B (en) 2022-12-01
SI3596041T1 (sl) 2023-02-28
RS63953B1 (sr) 2023-02-28
SMT202300097T1 (it) 2023-05-12
CA3056132A1 (en) 2018-09-20
DK3596041T3 (da) 2023-01-23
EP3596041A1 (en) 2020-01-22
IL268999B2 (en) 2023-04-01

Similar Documents

Publication Publication Date Title
IL268999B (en) Compounds and preparations for intracellular administration of medicinal agents
HUE057613T2 (hu) Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására
SI3394030T1 (sl) Sestave za doziranje sredstev v celice
SMT202200358T1 (it) Composizioni e metodi di rilascio degli agenti terapeutici
SG11202106144VA (en) Compositions for the delivery of therapeutic agents and methods of use and making thereof
IL287749A (en) Compositions for administering implantable drugs and methods of their use
IL271777A (en) Preparations for intravenous administration of medical substances
IL283627A (en) Improved transport of large materials
LT3103453T (lt) Vaisto kompozicija, apimanti diamino heterociklinį karboksamido junginį kaip aktyvų ingredientą
IL271596A (en) Preparations for administering drugs and methods of using them
EP3203995A4 (en) COMPOSITIONS AND METHODS OF DELIVERING THERAPY AGENTS
EP3525772A4 (en) FORMULATIONS FOR THE ENTERIC ADMINISTRATION OF THERAPEUTIC AGENTS
EP3654950A4 (en) MICROPARTICLE FORMULATIONS FOR THE DELIVERY OF ACTIVE INGREDIENTS
ZA202003079B (en) Pharmaceutical compositions comprising safinamide
HK1262230A1 (en) Compositions and methods for delivery of therapeutic agents
GB201809379D0 (en) Compositions and methods of transdermal delivery for therapeutic agents
HK40016365A (en) Formulations for enteric delivery of therapeutic agents
AU2017904492A0 (en) Compositions and methods for the delivery of agents that inhibit gene expression